PoggioF, Del MastroL, BruzzoneM, et al.Safety of systemic hormone replacement therapy in breast cancer survivors: A systematic review and meta-analysis. Breast Cancer Res Treat, 2022; 191(2):269–275.
2.
“The Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panell. The 2022 hormone therapy position statement of The North American Menopause society. Menopause, 2022; 29(7):767–794.
3.
HolmbergL, IversenOE, RudenstamCM, et al.Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst, 2008; 100(7):475–482.
4.
CrandallCJ, HoveyKM, AndrewsCA, et al.Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause, 2018; 25(1):11–20.
5.
Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: Individual participant meta-analysis of the worldwide epidemiological evidence. Lancet, 2019; 394(10204):1159–1168.
6.
Treatment of urogenital symptoms in individuals with a history of estrogen-dependent breast cancer: Clinical consensus. Obstet Gynecol, 2021; 138(6):950–960.
7.
SantenRJ, MirkinS, BernickB, et al.Systemic estradiol levels with low-dose vaginal estrogens. Menopause, 2020; 27(3):361–370.
8.
Casiano EvansEA, HobsonDTG, AschkenaziSO, et al.Nonestrogen therapies for treatment of genitourinary syndrome of menopause: A systematic review. Obstet Gynecol, 2023; 142(3):555–570.
9.
CruzVL, SteinerML, PompeiLM, et al.Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause, 2018; 25(1):21–28.
10.
LiFG, Maheux-LacroixS, DeansR, et al.Effect of fractional carbon dioxide laser vs sham treatment on symptom severity in women with postmenopausal vaginal symptoms: A randomized clinical trial. JAMA, 2021; 326(14):1381–1389.
11.
QuickAM, HundleyA, EvansC, et al.Long-term follow-up of fractional CO(2) laser therapy for genitourinary syndrome of menopause in breast cancer survivors. J Clin Med, 2022; 11(3):774.
12.
RossouwJE, AndersonGL, PrenticeRL, et al.Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women’s Health Initiative randomized controlled trial. JAMA, 2002; 288(3):321–333.
13.
The American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults. J Am Geriatr Soc, 2023; 71(7):2052–2081.
